Yunu is redefining how imaging powers clinical research. The company’s intelligent, end-to-end workflow platform streamlines every stage of imaging-based trials—from image capture and reader assignment to adjudication and data export—ensuring scientific integrity and operational efficiency. Trusted by life sciences, pharmaceutical, cancer centers, and research organizations worldwide, Yunu empowers teams to manage complex imaging studies with clarity, confidence, and speed. | Yunu provides medical research technology and services to life sciences companies and clinical research environments that perform precision imaging assessments. Yunu’s aim is to ensure breakthrough therapies are accessible to everyone by unifying medical imaging insights and connecting clinical communities. With thousands of clinical trials relying on the platform daily, Yunu is delivering a new standard for clinical trial imaging workflow. Learn more at https://www.yunu.io.
withZeta.ai by Lantern Pharma
withZeta.ai – the power and insights of thousands of experts, millions of publications, and billions of data points, focused on your rare cancer problem. A world’s deepest knowledge base focused on highly recursive, multi-agentic systems leveraging curated knowledge-bases and tools from Lantern Pharma to conquer rare cancer drug development and research.
Visiopharm Corporation
Visiopharm® is a leading provider of AI-driven precision pathology software for research and diagnostics. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader within clinical applications, with no less than eight diagnostic algorithms cleared under IVDR for EU customers. These applications provide diagnostic decision support and can be easily activated and integrated into existing lab workflows. Founded in 2002, Visiopharm is privately owned and operates internationally with over 750 customer accounts in more than 40 countries. The company’s headquarters are located in Denmark’s Medicon Valley, with legal entities in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.
VION Biosciences
VION Biosciences is a specialized life science platform company focused on manufacturing and supplying mission-critical reagents, specialty chemicals, and assay kits for research, diagnostics, and drug development. We provide integrated, high-quality materials—including lipid nanoparticles and custom formulations—from discovery to commercialization. VION Biosciences aims to accelerate scientific research and clinical testing through innovation and flexible manufacturing solutions.
Turbine
Turbine is virtualizing biological experiments with AI to accelerate drug discovery and improve clinical translatability. Using its foundational virtual cell model powered by its lab-in-the-loop, Turbine creates virtual copies of experimental assays. Running experiments at computational speed and scale allows researchers to test millions of ideas, beyond physical lab constraints, to understand biological drivers of disease. Working with scientists at leading biopharma like MSD (Merck & Co.), AstraZeneca and Bayer, Turbine’s virtual assays have rationalized experiments across more than 30 discovery programs. Backed by leading tech and industry investors like Accel, MSD Global Health Innovation Fund, Interactive Venture Partners and Beiersdorf, Turbine is turning biology into an engineering discipline.
TOMOCUBE
Tomocube develops holotomography (HT)-based 3D live cell imaging systems that enable label-free, non-invasive visualization of cancer cells, tumors, and organoids in real time. Our AI-integrated platform provides quantitative analysis of subcellular dynamics, cell volume, and dry mass — without phototoxicity or sample preparation artifacts — supporting oncology research from mechanistic studies to drug response assessment.
Tigermed
Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are collaborating with over 2,800 customers and committed to moving their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 180 locations with over 10,000 employees across Asia Pacific, Europe, North America, Latin America and Africa. We are devoted to building an integrated platform that enables the boundless possibilities for the healthcare industry, embracing challenges to fulfill our commitment to serving unmet patients’ needs, and ultimately saving lives. | Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are committed to moving our customers through their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 100 subsidiaries and 180 service locations, with over 10,000 employees across 54 countries in Asia Pacific, Europe, North & South America and Africa. We are devoted to building an integrated platform that enables boundless possibility for healthcare industry, embracing challenges to fulfill our commitment to serve unmet patients’ needs, and eventually saving lives. | Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are collaborating with over 3,200 customers and committed to moving their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 180 locations with over 10,000 employees across Asia Pacific, Europe, North America, Latin America and Africa. We are devoted to building an integrated platform that enables the boundless possibilities for the healthcare industry, embracing challenges to fulfill our commitment to serving unmet patients’ needs, and ultimately saving lives.
The Cancer Epitope Database and Analysis Resource (CEDAR)
The Cancer Epitope Database and Analysis Resource (CEDAR – cedar.iedb.org) is a freely available resource funded by NCI. It catalogs experimental data on antibody and T cell epitopes studied in humans in the context of cancer disease. CEDAR also hosts tools to assist in the prediction and analysis of cancer epitopes. CEDAR is a companion site to the Immune Epitope Database (IEDB – iedb.org), which is funded by NIAID, and houses epitope data on infectious disease, allergy, autoimmunity and transplantation.
Studylog Systems, Inc.
Used by over half of the top-20 pharmas, biotechs, and CROs globally, Studylog is the most powerful animal study management software available to in vivo researchers, technicians, and managers. Studylog reduces errors, effort, and time in the lab by planning and completing all of your study tasks. Run your studies more easily with built-in reproducibility practices, connect with devices, and digitize your data so results are available at your fingertips forever.
Shape Digital
Shape Digital is a software company transforming asset-intensive industries with applied AI solutions. Our approach combines first-principles models and artificial intelligence to enhance asset reliability, energy efficiency with a focus on CO₂ emissions reduction, and operational safety for the oil and gas sector. Live demonstrations will showcase Shape Lighthouse, Shape Aura, and Shape Reef, highlighting their real-world impact and the business value they deliver to O&G operators and service companies.